Abstract: Human-derived isogenic induced pluripotent stem cells (iPSCs) with copy number variation for alpha-synuclein, and methods of use thereof, are provided.

Abstract: Human-derived isogenic induced pluripotent stem cell (iPSCs) lines with copy number variation for alpha-synuclein, and methods of use thereof, are provided. Also disclosed are methods of modifying expression of alpha-synuclein gene using gene editing systems.

Abstract: The present invention provides methods for defining a disease or condition with a wide range of etiologies based on clustering of genes belong to the same biological pathway and observed frequencies or prevalence of various patient factors assessed in a given patient population, including motor and non-motor symptoms, neuropathology, age of onset, genetics, and involvement of peripheral autonomic system, including the enteric nervous system of the gastrointestinal (GI) system. Also disclosed herein are methods and kits for early diagnosis and treatment of subjects for multisystem Lewy body disease (MLBD), including Parkinson's disease, and/or one or more GI conditions that indicate a propensity for MLBD.

Abstract: Provided herein are methods, kits, and devices related to genetic variations of neurological disorders. For example, methods, kits, and devices for using such genetic variations to assess susceptibility of developing Multiple System Atrophy.

Abstract: Methods for inserting a polynucleotide sequence into the genome of a human cell are provided. The present methods result in insertion of a polynucleotide sequence of interest into the H11 locus in the genome of a human cell. Also provided are nucleic acids that include sequences for integrating a polynucleotide sequence of interest into the H11 locus in the genome of a human cell. A transgenic human cell including site specific recombination sites at the H11 locus is also disclosed.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Disclosed herein are in vitro and in vivo methods for screening for compounds that treat diseases and conditions that are related to oxidative stress such as Parkinson's disease

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Methods for inserting a polynucleotide sequence into the genome of a human cell are provided. The present methods result in insertion of a polynucleotide sequence of interest into the H11 locus in the genome of a human cell. Also provided are nucleic acids that include sequences for integrating a polynucleotide sequence of interest into the H11 locus in the genome of a human cell. A transgenic human cell including site specific recombination sites at the H11 locus is also disclosed.

Abstract: Compositions and methods are provided for treating a disorder characterized by ?-synuclein dysfunction and/or altered lipid metabolism.

Abstract: Human-derived fibroblast cells with copy number variation for alpha-synuclein, and methods of use thereof, are provided. For example, compositions and methods for high through-put screening of potential therapies for neurodegenerative disease such as Parkinson's disease are provided.

Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.

Abstract: Disclosed herein are methods and compositions for alteration of an LRRK2 gene in a fibroblast or iPSC.

Abstract: Compositions and methods are provided for treating a disorder characterized by ?-synuclein dysfunction and/or altered lipid metabolism.

Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.